The Department of Veterans Affairs (VISN 3) Healthcare Network intends to negotiate a multi-award agreement with the following Food and Drug Administration (FDA) approved General Services Administration (GSA) companies to provide control and preventative measures for the active surveillance of Methicillin-Resistant Staphylococcus aureus (MRSA): Cepheid, 904 Caribbean Drive Sunnyvale, California 94089 for its GeneXpert System. The GeneXpert System combines sample preparation with real-time PCR amplification and detection for fully integrated and automated nucleic acid analysis. The systemýýýs capability enables users to perform up to 16 different molecular tests concurrently. Specimens can be processed as they come in, 24/7, 365 days a year. BD Diagnostics GeneOhm, 6146 Nancy Ridge Drive San Diego, California 92121 for its Smart Cycler Desktop System. The Smart Cycler Desktop System provides the government with a cost-effective, accurate and rapid means to detect MRSA colonization. When dealing with large numbers of specimens, the achromopeptidase lysis method offers easier processing than the kit recommended method without negatively affecting PCR sensitivity or specificity. Clinical research indicates that the implementation of universal surveillance, which introduces the testing of all admitted patients, is far more effective than just passive or targeted active surveillance when monitoring for Methicillin-Resistant Staphyloccus aureus (MRSA). The purpose of this acquisition is to reduce and or mitigate the spread of Methicillin-Resistant Staphyloccus aureus (MRSA) throughout VISN 3ýýýs Healthcare Network through active surveillance of cultures. The procurement of the outlined product offerings will add the required value in the management of multi-drug resistant organisms within VISN 3.

Bid Protests Not Available